Gram-negative infection is an important cause of morbidity and mortality after unrelated donor-bone marrow transplantation (UD-BMT). We performed a retrospective case-control study to examine the risk factors, prophylaxis, therapy and outcome of Gram-negative bacteraemia (GNB) in 428 patients undergoing UD-BMT. The incidence of GNB was 3.6% in children and 19% in adults. Of the adults, 11% developed GNB 460 days post UD-BMT. Predisposing risk factors for GNB included 'high-risk' disease status, chronic graft-versushost disease and use of systemic steroids. Fever, a raised C-reactive protein (CRP) and hypotension were common findings at presentation. Patients were routinely given prophylactic ciprofloxacin: resistance to this antibiotic was seen in 33% of isolates. We identified an age-matched control group undergoing UD-BMT over the same time period as the study group. Gram-positive bacteraemia was significantly more common in cases than controls. Mortality from GNB was 17% in children and 24% in adults. We conclude that GNB is a common complication of UD-BMT with a high associated mortality. Patients should be educated further to present rapidly with symptoms suggestive of infection.
bacteraemia; unrelated donor; case-control study Infection is an important cause of morbidity and mortality after unrelated bone marrow transplantation (UD-BMT). [1] [2] [3] Viral, fungal and possibly bacterial infections are more common than after sibling allografts. This is due to severe immune deficiency as a consequence of pretransplant radiation, chemotherapy and immunosuppression, prolonged neutropenia before engraftment and a slow recovery of the immune system post transplant. Continued deficiency of immunoglobulins, in particular IgG, renders the patient unable to opsonise encapsulated bacteria. 4 In addition, a low serum IgA, 2 mucosal breaches resulting from the conditioning regimen and multiple invasive procedures, facilitates transmucosal bacterial spread. Immunosuppressive agents and the immune suppression of graft-versus-host disease (GVHD) per se also contribute.
Early diagnosis and prompt treatment of infections may improve the outcome of UD-BMT. The early diagnosis of cytomegalovirus (CMV) reactivation and infection by PCR and antigen testing is a major recent advance, resulting in a decrease in both morbidity and mortality, particularly in the first 3 months post transplant. The diagnosis and therapy of fungal infection post allograft is still far from optimal and mortality from such infections is very high. 1 We have previously found a significant incidence of Gram-negative infections post UD-BMT and a high associated mortality. 1 This study greatly extends previous findings in a much larger patient population that now includes children. Gram-negative bacteraemia (GNB) occurred frequently after day 100 post transplant. Using UD-BMT case-controls from our unit, we analysed the risk factors, timing, therapy and outcomes of patients who had GNB after unrelated bone marrow transplant and suggest ways in which the outcome may be improved.
Patients and methods

Patients and definitions
The study is a retrospective review of infection in all UD-BMT patients (children and adults) treated at the Bone Marrow Transplant Unit, Bristol Royal Hospital for Children, United Bristol Healthcare Trust, between September 1987 and September 2001. The unit is a tertiary referral centre for children and adults specialising in alternative donor transplantation. Patients with GNB were identified from the computerised records of the Bristol Public Health Laboratory (PHLS, UK). For each patient (case) with GNB, two age-matched controls without GNB were randomly selected from all patients undergoing UD-BMT during the study period. The matching was for the following broad age groups: 0-4, 5-9, 10-14, 15-17, 18-19, 20-29, 30 -39, 40-49 and 50 þ years of age. The clinical records of all cases and controls were reviewed. Patients were considered to be of standard haematological risk if in first or second remission with acute leukaemia (ALL or AML), in first chronic phase with chronic myeloid leukaemia (CML) or with a diagnosis of refractory anaemia with excess blasts (RAEB). All other patients, including those with a diagnosis of acute leukaemia in third or greater remission or in relapse, CML in accelerated phase or blast crisis, chronic lymphocytic leukaemia (CLL) or aplastic anaemia, were considered to be high risk, both for relapse and for transplant-related mortality.
Conditioning regimens
Predominantly, patients were conditioned for UD-BMT with cyclophosphamide (120 mg/kg), TBI (14.4Gy in eight fractions) and Campath antibodies as previously described.
Marrow and PBSC procurement and processing
The target dose harvested was 4 Â 10 8 nucleated cells or 2.5 Â 10 6 CD34 þ cells per kilogram of recipient weight. Grafts were, in general, T-cell depleted with Campath antibodies (ex vivo using CAMPATH 1M and AB serum as a source of complement, or in vivo with intravenous CAMPATH 1G or 1H) or CD34 selected with or without a T-cell add-back at day 0.
GVHD prophylaxis and treatment
Cyclosporin A was given from day À1 and tapered at 3-6 months in the absence of GVHD. The dose was modified to maintain levels of 100-225 nmol/l. Methotrexate was given on days 1, 3 and 6 to the recipients of mismatched grafts followed by folinic acid rescue. Acute and chronic GVHD were categorised as being absent or present. The use of systemic steroids (oral or intravenous) for the treatment of GVHD was recorded.
Engraftment
The day of engraftment was defined as the first of 3 consecutive days on which the absolute neutrophil count (ANC) remained at or above 0.5 Â 10 9 /l. G-CSF was given from day þ 10 and continued until the ANC remained above 1 Â 10 9 /l for 3 consecutive days.
Supportive care, prophylaxis and treatment of infection
All patients were nursed in protective isolation with HEPA filtration from day 0 until engraftment. A 'clean' diet (low in bacterial pathogens) was used from day À3 until 30 days after discharge from isolation. Total parenteral nutrition was given to those patients unable to maintain an adequate oral intake. Oral ciprofloxacin was commenced on day À3 and continued until intravenous antibiotics were required. Ciprofloxacin was recommenced on cessation of intravenous antibiotics, and continued in adults until day 75. Some children were intolerant of ciprofloxacin; they did not receive prophylactic antibiotics. Co-trimoxazole was commenced on day þ 28 as Pneumocystis carinii prophylaxis and continued for 6-12 months. Patients at low risk of CMV disease (both recipient and donor seronegative) received low-dose oral acyclovir from day À4 for 6 months. Patients at high risk of CMV disease (recipient or donor CMV seropositive) received high-dose acyclovir and intravenous immunoglobulin every 3 weeks commencing on day À1 for 3 months. All patients received oral itraconazole suspension from day À3 as antifungal prophylaxis.
Febrile neutropenia (defined as pyrexia of 381C on two or more occasions within 1 h, or by a single episode of pyrexia of 38.51C or more in a patient with an ANC o1 Â 10 9 /l) was treated with broad-spectrum intravenous antibiotics (piperacillin/tazobactam and gentamicin). Antistaphylococcal cover (teicoplanin) was added for fever persisting for 448 h. Patients not responding to piperacillin/tazobactam and gentamicin were changed to meropenem after 96 h. Antibiotics were modified according to the sensitivity of all organisms isolated. Amphotericin or, more recently, liposomal amphotericin was added in patients with persistent fever (472 h) or suspected fungal infection.
Microbiological methods and documentation of infection
The computerised records of the Bristol Public Health Laboratory (PHLS, UK) were retrospectively reviewed to identify all UD-BMT patients in whom blood cultures grew Gram-negative bacteria on one or more occasions. The microbiological records of these patients were reviewed with reference to the infecting organism(s), the antibacterial sensitivities of the organism, the date of positive culture and the time following transplant. Any concurrent clinical specimens, including samples of urine, sputum, bronchoalveolar lavage fluid, central lines swabs and surface swabs, were also examined for evidence of Gram-negative isolates. The occurrence of Gram-positive bacteraemia and proven fungal infection, and their timing in relation to the date of BMT were noted for cases and controls.
All samples were handled using standard microbiological methods (PHLS 1997) . Blood cultures were processed by an automated system (Bactec, Benton Dickinson until 1994, and BacT/Alert Organon Teknika thereafter) and were incubated for 5 days. All Gram-negative organisms were identified using standard laboratory methods or API (Analytical Profile Index, bio-Merieux, Lyon, France). Antimicrobial sensitivity testing was performed on all Gram-negative blood culture isolates using the Stokes comparative method and the British Society for Antimicrobial Chemotherapy standardised disc diffusion method. Organisms that could not be identified by these means were sent to PHLS reference laboratories. Acinetobacter were identified to genus level only.
CMV surveillance and diagnosis and the identification of fungal infection have been previously described. 1, 5 CMV infection was treated with ganciclovir.
Clinical data
The clinical records of all cases and controls were examined. For each episode of Gram-negative sepsis, clinical information pertaining to the presence of fever, hypotension (420 mmHg drop in BP in children, systolic BP o90 mmHg in adults), central line exit site infection, associated clinical symptoms, time to defervescence, the ANC and the C-reactive protein (CRP) at presentation were extracted from the notes.
Following transplantation, adult patients were followed long-term in the BMT outpatient department at Bristol Children's Hospital. Paediatric patients, however, were discharged back to their referring hospital and only reviewed at the unit every 3 months. To ensure accurate reporting of the incidence of GNB in paediatric patients, data for them are reported only until discharge. Data for adult patients were collected until July 2001, or until the time of relapse.
Statistics
Children and adults were analysed separately as there were possible differences between them in prophylaxis and follow-up. In children, the mean hospital stay following UD-BMT prior to discharge was 60 days. The 'cases' in children were all therefore within 60 days of BMT; it is possible that the group regarded as 'controls' may have had GNB at some later, unknown time. Since follow-up was longer for adults, GNB occurred for the first time 460 days post transplant for some adults; the control group, however, was more sharply defined than that of the children.
Comparisons of proportions between cases and controls were made using continuity-corrected 2 Â 2 w 2 tests, or Fisher's exact tests where expected frequencies were small. Mann-Whitney U-tests were used to compare total nucleated cell (TNC) doses and days to engraftment.
The date of data analysis was 15 February 2002.
Results
Between September 1987 and September 2001, 428 UD-BMT adult and paediatric patients (90 adults 418 years, 338 children) were treated at the Bristol Royal Hospital for Children. Following UD-BMT, the mean in-patient stay for children was 32 days (range 19-74 days), and the mean follow-up in Bristol prior to discharge was 60 days (range 28-123 days). Data for children were analysed to day 60 only. Following discharge, adults undergo long-term follow-up in the outpatient department. In total, 29 patients (12 children and 17 adults) had one or more episodes of GNB. Of these, 12 children (3.6%) and seven adults (8%) had one or more episode of GNB in the first 60 days. In all, 10 adults (11%) had one or more episode of GNB 460 days after transplantation. The overall incidence of GNB in adults was 19%. The clinical characteristics of the 29 cases and 58 controls are shown in Table 1 . The median follow-up of five surviving adult cases and 23 surviving adult controls was 4.9 years (range 0.1-9.2 years) and 5.7 years (range 0.1-9.2 years), respectively. There were no differences in sex and diagnosis between cases and controls. There were significantly more high-risk patients in the adult cases (53%) than in adult controls (12%) (P ¼ 0.005).
Cell dose and engraftment
The median TNC dose was 5.8 Â 10 /kg (range 2.21-15.68) for adult cases and controls, respectively (P ¼ 0.964). There was no significant difference in the use of T-cell depletion or in time to engraftment between cases and controls. Three cases (one child and two adults) died prior to engraftment at days þ 3, þ 9 and þ 19 due to complications of septicaemia (disseminated intravascular coagulopathy, septicaemia with multiorgan failure and pulmonary haemorrhage, respectively). Primary graft failure did not occur in any cases and occurred in three controls, who subsequently died at days þ 28, þ 40 and þ 82. One control patient died at day þ 12 from venoocclusive disease and multiorgan failure.
Gram-negative bacteraemia
A total of 29 UD-BMT cases (12 children and 17 adults) had one or more episodes of GNB (43 Gram-negative isolates, 38 episodes of GNB). The organisms isolated are shown in Table 2 .
In all, 15 episodes of GNB occurred in the 12 children (15 isolates) and three children had two episodes of GNB. GNB occurred at a median of 6 days post transplantation (range À10 to 50 days). One child (8%) died on day þ 3 post transplantation from complications of GNB.
In total, 23 episodes of GNB occurred in 17 adults. Eight episodes of GNB occurred in seven adults o60 days post UD-BMT (eight isolates) and one of these seven adults had two episodes of GNB. None of these adults had GNB 460 days post UD-BMT. In total 15 episodes of GNB occurred in 10 adults 460 days after UD-BMT (20 isolates), and five of 10 adults had two episodes of GNB. Four adults had episodes of GNB in which multiple isolates were identified, all occurring 460 days post UD-BMT. Overall, adults developed GNB at a median of 83 days post transplantation (mean þ 193 days, range À3 to þ 1183 days). Of the 10 adults who developed GNB 460 days post UD-BMT, all were receiving steroids at the time of bacteraemia (nine for GVHD and one for ITP). Five of the 10 adults receiving steroids had two episodes of GNB. Three of the 10 adults had multiple organisms isolated during episodes of GNB. No other adult or paediatric cases had more than one organism isolated during episodes of GNB. Four adults (24%) died on days þ 9, þ 40, þ 68 and þ 125 post transplantation due to complications of GNB.
In two cases with GNB (7%), the infecting organism was also isolated from other sites (one from urine and one from BAL fluid).
Clinical features of GNB
In children, the most common clinical feature at presentation of GNB was fever 4381C, present in 11 of 14 episodes (79%) of GNB in which there was documentation of the temperature on admission (Table 3) . Common symptoms included abdominal symptoms (3/14, 21%) and skin lesions (3/14, 21%). The CRP was elevated in all episodes in which it was documented, with a mean of 103 mg/l (range 24-226 mg/l, normal o10 mg/l). The median neutrophil count was 0.0 Â 10 9 /l (range 0.0-3.3 Â 10 9 /l). Hypotension complicated 3/14 (21%) episodes of GNB, all caused by Escherichia coli. One child presenting with hypotension died directly from GNB.
In adults, fever 4381C occurred in 11 of 22 episodes (50%) of GNB in which there was documentation of the temperature at admission. Common symptoms included CNS symptoms, such as headache, seizures and lethargy (5/ 22, 23%), back pain (3/22, 14%) and respiratory symptoms (3/22, 14%). The CRP was elevated in all episodes in which it was documented, with a mean of 102 mg/l (range 31-333 mg/l). Hypotension complicated 5/17 (29%) episodes of GNB in five adults, three of whom died of GNB. In total, five children and adults presented with hypotension: three had E. coli, one had Enterobacter and one had Pseudomonas isolated.
GVHD
In children, there was no significant difference in the incidence of acute GVHD between cases and controls (three cases and seven controls developed acute GVHD, P ¼ 0.773). Three cases (27%) and five controls (21%) received systemic steroids for acute GVHD (P ¼ 0.990).
In adults, nine cases (53%) and 12 controls (35%) had evidence of acute GVHD (P ¼ 0.365). Seven cases (58%) and six controls (18%) developed chronic GVHD (P ¼ 0.020). Three cases (18%) and 21 controls (62%) had no evidence of acute or chronic GVHD (P ¼ 0.063). In total, 14 cases (82%) and 13 controls (38%) received systemic steroids for either acute or chronic GVHD (P ¼ 0.007).
CMV infection
In children, nine of 12 cases (75%) and 10 of 24 (42%) controls were high risk for CMV reactivation or disease (P ¼ 0.125). No cases and two of 10 controls (20%) had CMV reactivation. Two of nine cases (22%) and one of 24 controls, all of whom were on systemic steroids, had CMV disease.
In adults, 10 of 17 cases (59%) and 18 of 34 controls (53%) were high risk for CMV reactivation (P ¼ 0.921). CMV reactivation occurred in two of 10 high-risk cases (20%) and three of 18 controls (17%), all of whom were on systemic steroids. Two of 10 cases (20%), both on systemic steroid therapy, and one of 18 controls developed CMV disease.
Ciprofloxacin prophylaxis
Four of 12 cases and three of 24 controls o18 years of age were intolerant to ciprofloxacin and did not receive prophylactic antibiotics. Ciprofloxacin prophylaxis was given to all adults.
Antibiotic resistance
In children, ciprofloxacin resistance was documented in five of 15 isolates (33%) from four cases, and four of these five isolates (80%) were also resistant to gentamicin. Two of the four cases were given prophylactic ciprofloxacin during transplantation. In total, a third of the isolates identified in children were resistant to gentamicin. One isolate was resistant to piperacillin/tazobactam (first-line antibiotic therapy); however, it was sensitive to both gentamicin and meropenem. The two isolates of Stenotrophomonas maltophilia were, as expected, resistant to meropenem.
In adults, ciprofloxacin resistance occurred in 17 of 28 isolates (61%) in 12 cases. Seven of the 17 isolates (41%) were also resistant to gentamicin. Ciprofloxacin-resistant isolates were found in six cases (60%) presenting with GNB after day 60. In total, eight of the isolates found in adults were resistant to gentamicin (29%). One of the gentamicinresistant isolates was also resistant to piperacillin/tazobactam, but sensitive to meropenem. Five isolates were resistant to piperacillin/tazobactam; all were sensitive to meropenem. Two isolates (one Stenotrophomonas maltophilia, one Flavobacterium indologenes) were both meropenem and gentamicin resistant.
The incidence of overall ciprofloxacin resistance has not been constant, occurring in 57% of isolates in 1994-1997 and 23% in 1998-2001.
Gram-positive bacteraemia
In children, five cases (42%, 10 episodes, 11 isolates) and three controls (13%, four episodes, six isolates) had Grampositive organisms isolated from blood cultures on one or more occasions, as shown in Table 4 (P ¼ 0.124).
In adults, 14 cases (82%, 21 episodes, 25 isolates) and five controls (15%, nine episodes, 10 isolates) had Grampositive bacteraemia (GPB) (Po0.001). GPB occurred after day 60 in nine cases (13 episodes) and two controls (three episodes).
Fungal infection
There were three proven fungal infections with Aspergillus fumigatus in three cases. All were adults and all were receiving systemic steroid therapy. Two cases died from invasive Aspergillosis and the third case died from GNB. One control 418 years old is alive after a proven Aspergillus spp. infection.
Survival
In children, a total of nine cases (75%) and eight controls (33%) have died (P ¼ 0.045). One case died on day þ 3 post transplantation from complications of GNB. Eight cases have subsequently died: one from complications of GNB, one from acute chronic pneumonitis and six from relapse of disease. In children, the mortality rate from complications of GNB was 17% (2/12).
In adults, 12 cases (71%) and 11 controls (32%) have died (P ¼ 0.022). Four adults died on days þ 9, þ 40, þ 68 and þ 125 post transplantation due to complications of GNB. The mortality rate from GNB in adults was 24% (4/17).
Discussion
This study systematically analysed all patients with GNB from a cohort of 428 UD-BMT recipients. We have demonstrated that GNB is a common complication of UD-BMT in both children and adults. GNB has a high mortality rate and often occurs late after transplantation. Patients particularly at risk of GNB include 'high-risk' Table 4 Gram-positive organisms isolated in blood cultures from 29 cases and 58 controls adult patients, those with chronic GVHD and patients receiving systemic steroid therapy. A number of factors may predispose UD-BMT patients to GNB, including highdose chemoradiotherapy conditioning regimens, T-cell depletion of the graft, immunosuppressive therapy and the development of GVHD. The resultant deficits in cellmediated and humoral immune function may persist for many months after transplantation and place patients at risk of GNB. 6 All studies of infection are susceptible to over-and underascertainment. We have reported only laboratoryconfirmed Gram-negative infections. We believe that our data provide a realistic representation of the incidence and outcome of early GNB in both adults and children and of late GNB in adults.
It has previously been demonstrated that poor-risk underlying disease is a risk factor for bacteraemia in the pre-engraftment period. 7 We found that 'high-risk' adult transplant recipients were also at risk for GNB post engraftment. 'High-risk' patients may have undergone intensive and often prolonged pretransplant chemotherapy, and may require more intensive transplant conditioning regimens to eradicate their chemoresistant disease. Prior to conditioning, 'high-risk' patients may have pre-existing lymphopenia and neutropenia and often have severely depressed immunoglobulin levels. Intensive conditioning regimens worsen these immune deficits and result in prolonged and profound neutropenia and monocytopenia. The high-dose chemoradiotherapy conditioning regimens used for UD-BMT may cause severe mucositis with disruption of mucosal barriers, thus providing a portal of entry for GNbacteria.
The incidence of GNB was significantly increased in patients receiving systemic steroid therapy for GVHD. Both chronic and acute GVHD are known risk factors for bacteraemia in allogeneic transplant recipients. 7 Chronic GVHD may cause profound immunodeficiency with depletion of B-and T-cells, impairment of lymphocyte function and neutropenia. 8 The immunosuppression required to treat chronic GVHD compounds this preexisting immunodeficiency. Regular use of intravenous immunoglobulin to correct the hypogammaglobulinaemia may improve the opsonising activity of the serum, and hence render patients with chronic GVHD less susceptible to bacterial infections, although the use of immunoglobulin may also delay immune reconstitution. 9 Systemic steroid therapy, whether for chronic GVHD or for other immune conditions, impairs T-cell activation, inhibits antigen presentation and impairs monocyte and neutrophil function, thus further increasing susceptibility to infection with Gram-negative organisms. 10 Patients with GNB appeared to have a higher incidence of CMV infection, although this did not reach statistical significance. Viral infections per se are immunosuppressive and may cause lymphopenia, even in persons with normal immune function. 11 Marrow suppression and neutropenia may result from both the CMV infection and from treatment of CMV with ganciclovir. CMV infection also predisposes patients to GVHD, which, in turn, may favour bacterial infection. In addition, CMV involvement of the gut may lead to mucosal damage from overproduction of proinflammatory cytokines 12 and direct viral cytopathic effects, providing a portal of entry for bacteria.
Although patient numbers are small, there appears to be an increase in the incidence of fungal infection in patients with GNB when compared to controls. The relationship between fungal infection and GNB may be complex. We have previously demonstrated an increased risk of invasive fungal infection in patients with two or more episodes of bacteraemia. 1 During the first 60 days post BMT, bacteraemia is associated with early death from invasive fungal infection. 13 All invasive fungal infections in our patients were diagnosed after 60 days, usually in patients on systemic steroid therapy for GVHD. Fungal infection itself may cause local tissue damage and steroid therapy may impair immune responses, thus predisposing to bacterial superinfection.
The mortality of GNB was high in our patients. This suggests that not only is GNB a serious complication of UD-BMT, but also that patients may be presenting to hospital late. Approximately one-quarter of the patients with GNB had hypotension at presentation. The majority of patients with GNB were febrile despite being on intensive immunosuppressive therapy. Fever in an UD-BMT patient should therefore prompt early presentation to hospital and thorough investigation for signs of infection. Further patient education prior to discharge from hospital and easy access to appropriate medical services might prompt patients to present early in the course of sepsis and improve the outcome of GNB. Weekly stool surveillance cultures in 'high-risk' patients and in those with multiple risk factors may allow for early identification of Pseudomonas aeruginosa;
14 however, the incidence of GNB due to P. aeruginosa in our study was low. The use of regular surveillance blood cultures to detect subclinical or asymptomatic infection would be both costly and time consuming. However, if targeted at 'high-risk' patients, it might prove beneficial. 15, 16 As has been shown in previous studies, 17 an increase in the CRP was associated with GNB. Elevation of the CRP can be used as an early marker of transplant-related complications, with a very high CRP being predictive of severe transplant-related complications and mortality. 18 We have found daily in-patient monitoring of CRP to be beneficial as an early marker for infection, with changes in the CRP sometimes predating fever or other clinical symptoms (Marks, unpublished data ). An elevated CRP in a BMT patient attending for follow-up usually prompts us to perform an infection screen and, again, this has led to a diagnosis of bacteraemia in asymptomatic patients.
Selective gut decontamination with prophylactic oral ciprofloxacin has been shown to reduce Gram-negative bacterial infections in both allogeneic and autologous transplant recipients. [19] [20] [21] [22] There are concerns, however, that the use of prophylaxis will increase the incidence of ciprofloxacin-resistant organisms. 23, 24 In this study, resistance to ciprofloxacin was noted in nearly half of isolates. Unlike other studies, 23, 24 the incidence of ciprofloxacin resistance appears to have decreased with time although the use of prophylaxis has not changed. Interestingly, in cases presenting with GNB 4day þ 60, 50% of isolates were resistant to ciprofloxacin, suggesting long-term colonisation with resistant organisms. We find little evidence from this study to support extended ciprofloxacin prophylaxis and will be reverting to a shorter duration. The high incidence of ciprofloxacin resistance demonstrated in this study and reported elsewhere 23, 24 suggests that the role of ciprofloxacin prophylaxis should be re-evaluated, perhaps by a prospective randomised study. The use of oral fluoroquinolones has been linked to an increase in infections due to Gram-positive organisms, particularly Viridans Streptococci. 25, 26 We found a higher incidence of Gram-positive infection in patients with GNB when compared to the control group. Whenever possible, all BMT patients in our unit receive ciprofloxacin prophylaxis; hence, this finding is not due to differential fluoroquinolone exposure. The rate of GPB in our control population was similar to that reported by other authors; 27 hence, the factors that predispose BMT patients to GNB also appear to increase the risk of GPB. Despite selective gut decontamination, 40% of children may carry Gramnegative organisms and yeasts in their digestive tract. 28 The value of regular surveillance cultures remains unclear, 15, 16 but this is one potential way of diagnosing GNB earlier. Of course, surveillance cultures are positive in some patients due to contamination, which might lead to some patients being unnecessarily treated. There does however appear to be a correlation between colonisation with P. aeruginosa and later occurrence of P. aeruginosa bacteraemia.
14 Early treatment with anti-pseudomonal therapy may decrease the incidence of GNB in these patients.
Resistance to first-line empirical antibiotic therapy was also common, with 42% of the isolates being resistant to gentamicin and/or piperacillin/tazobactam. It is clearly important to modify antibiotic treatment in the light of sensitivity testing, but our data also reinforce the need to consider an early change in antibiotic treatment in those who clinically fail to respond to first-line therapy. Our third-line empirical antibiotic treatment is with meropenem, which, at present, appears to be appropriate therapy. In total, four isolates were resistant to meropenem. Three of these isolates were Stenotrophomonas maltophilia, a bacteria that is invariably resistant to meropenem.
In summary, GNB is a common and potentially lifethreatening complication of UD-BMT and may present late after transplantation. Patients most at risk are 'high-risk' transplant candidates and those who develop chronic GVHD or require treatment with systemic steroids. Various strategies may help to reduce the incidence of GNB in this population. The use of prophylactic ciprofloxacin-commenced pretransplantation is of proven benefit in reducing GNB, although the emergence of resistant strains is of some concern. Prevention of GVHD by T-cell depletion and minimisation of the use of steroids may also reduce the incidence of GNB post UD-BMT. Elevation of the CRP may be a useful warning sign. Of equal importance in improving the morbidity and mortality from GNB is the necessity to educate patients to present rapidly with symptoms suggestive of infection.
